KIF18A Inhibitor Clinical Trials FDA Approved KIF18A Targeting Therapies Market Report
KIF18A Therapy Commercial Launch Expected By 2030 Says Kuick Research in New Research Study
Delhi, June 24, 2025 (GLOBE NEWSWIRE) -- Global KIF18A Targeting Therapies Market Trends, Clinical Trials, Technology Platforms & Future Outlook 2025 Report Highlights & Findings:
First KIF18A Targeting Therapy Commercial Availability Expected By 2030
Highest Phase Of Development: Phase-I/II
KIF18A Targeting Therapies In Clinical Trials: > 10 Therapies
KIF18A Targeting Therapies Clinical Trials Insight By Company, Country, Indication & Phase
KIF18A Targeting Therapies Market Development Trends Insight
KIF18A Therapies Technology Platforms Insight
Download Report: https://www.kuickresearch.com/report-kif18a-targeting-inhibitor-kif18a-inhibitor-clinical-trials-kif18a-targeting-therapy
The global oncology landscape is witnessing rapid progress in precision medicine, and one of the most lead nominees in emerging targets is Kinesin Family Member 18A (KIF18A). It is a mitotic motor protein that is essential for chromosome alignment during mitosis, which facilitates proper segregation of chromosomes. Its perturbation leads to genomic instability, which is a distinguishing feature of cancer. Extrapolations of KIF18A have also been seen in various cancers such as ovarian and breast cancer, with an association with prognosis, drug resistance, and the potential to metastasize. As a crucial protein involved in mitosis and overexpression in cancer, KIF18A is now a promising therapeutic target.
Targeting KIF18A interferes with mitotic mechanisms in chromosomally unstable (CIN-positive) cancer cells, causing selective death of cancer cells. In contrast to conventional chemotherapies, which indiscriminately impact all proliferating cells, KIF18A inhibitors provide a more selective and less toxic option by taking advantage of cancer cells' vulnerability to proper mitosis. The major approach is small molecule inhibitors that disrupt KIF18A's motor activity, hindering it from modulating microtubule dynamics at the kinetochore. It leads to mitotic arrest and failure of chromosome alignment, ultimately triggering apoptosis in cancer cells.
Clinical development is progressing well. Volastra Therapeutics, a forerunner in this arena, is developing two KIF18A-targeting molecules: Sovilnesib (AMG650), acquired from Amgen and underway in Phase I trials for platinum-resistant high-grade serous ovarian cancer, and VLS-1488, an in-house oral inhibitor in Phase I/II. Both molecules displayed favorable safety profiles and early anti-tumor effects, with particular efficacy in high-chromosomal-instability tumors. Volastra's pipeline demonstrates the therapeutic potential of inhibiting KIF18A to treat difficult-to-treat cancers.
Accent Therapeutics is also advancing with ATX-295, an oral KIF18A inhibitor in initial clinical testing for solid tumors such as triple-negative breast and high-grade serous ovarian cancers. Their biomarker strategy makes use of genomic instability markers such as whole-genome doubling to better optimize patient selection and optimize therapy outcomes.
AI based drug discovery is providing additional impetus to this area. Insilico Medicine has utilized proprietary platforms such as Chemistry42 and PandaOmics to discover ISM9682, a new macrocyclic KIF18A inhibitor with high preclinical efficacy. The AI platforms facilitate rapid optimization of candidates with increased specificity and pharmacological profiles, highlighting the growing use of sophisticated computational approaches in drug discovery.
Aside from clinical advancement, the market opportunity for KIF18A inhibitors is also robust. As precision oncology gains more attention, the therapies are well poised to capture the opportunity of targeted therapies, particularly in diseases that are refractory to current treatments. Various companies, including Nvidia-funded Iambic Therapeutics, Aurigene Oncology, Simcere Zaiming Pharmaceutical, and Amgen, are developing promising product candidates in preclinical phases.
Overall, the KIF18A-targeted therapy market is changing very quickly, powered by strong scientific justification, initial clinical success, and novel development approaches. As additional preclinical and clinical information becomes available, the market has significant potential for strong growth, powered by partnerships, application of artificial intelligence and machine learning tactics, and the overall dedication to creating targeted and individualized cancer therapeutics.
CONTACT: Neeraj Chawla Research Head Kuick Research neeraj@kuickresearch.com https://www.kuickresearch.com/Sign in to access your portfolio
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Bloomberg
an hour ago
- Bloomberg
China's Only Iran Option Is a Low Profile
China's cautious posture in the Iran-Israel conflict has revealed the limits of its ambitions — and options — as a global diplomatic player. The world's second-largest economy likes to position itself as a stabilizing force, offering a sharp contrast to President Donald Trump's America First approach. The Middle East conflict was a litmus test of great power diplomacy, but Beijing didn't rise to the occasion. Instead, it is Trump who has — for the moment at least — declared a ceasefire, showing that Washington can still de-escalate a crisis (after escalating it by carrying out strikes on Iranian nuclear sites.)
CNN
an hour ago
- CNN
Stunning amber fossil reveals ‘Last of Us'-type fungus likely lived alongside dinosaurs
A glob of 99 million-year-old amber has preserved an ancient fly in horror show fashion: with the mushroom-like fruiting body of zombie fungus bursting forth from its head. The insect, along with a second specimen of a young ant infected with a similar fungus, are two of the oldest examples of a bizarre natural phenomenon that involves fungal parasites hijacking the bodies of their hosts before ultimately killing them. 'Amber gives us this opportunity to visualize the ancient ecological relationships preserved in fossils,' said Yuhui Zhuang, a doctoral student at the Institute of Paleontology at Yunnan University in southwestern China. 'Overall, these two fossils are very rare, at least among the tens of thousands of amber specimens we've seen, and only a few have preserved the symbiotic relationship between fungi and insects,' added Zhuang, the lead author of a study on the fossils published June 11 in the journal Proceedings of the Royal Society B: Biological Sciences. Zhuang and his colleagues named two previously unknown species of ancient fungi of the genus Ophiocordyceps from their research on the amber, which involved using optical microscopes to study the tiny pieces of amber and micro-computed tomography to make 3D images of the fungi-infected insects. They found the first, named Paleoophiocordyceps gerontoformicae, on the ant and the second, Paleoophiocordyceps ironomyiae, on the fly. Some Ophiocordyceps species that prey on ant species today are known as 'zombie-ant fungi' because the fungal parasite can manipulate the behavior of its hosts for its own benefit. The phenomenon inspired the video game behind the HBO TV show 'The Last of Us.' HBO shares a parent company, Warner Bros. Discovery, with CNN. 'The discovery of these two fossils suggests that terrestrial ecosystems were already very complex, and that Ophiocordyceps, in particular, may have begun to act as 'predators' of insects in the Cretaceous period, regulating the populations of certain groups,' Zhuang said via email. Today, parasitic fungi, also known as entomopathogenic fungi, infect a wide range of insect groups, including ants, flies, spiders, cicadas and beetles, according to London's Natural History Museum. In the case of carpenter ants, the spore of the Ophiocordyceps fungus lands on the head of an ant, enters its brain through a weak area in the insect's exoskeleton and takes control of the ant to facilitate its spread, said Conrad Labandeira, senior scientist and curator of fossil arthropods at the Smithsonian Museum of Natural History in Washington, DC, who wasn't involved in the study. Paleoophiocordyceps likely zombified its hosts in similar ways, according to Labandeira. 'It appears that ants, for some reason, were targeted early for zombification, and currently are the major recipients of this parasitoid fungus,' Labandeira said. He added that flies are only rarely affected by these parasitic fungi today, making a fossilized example particularly interesting. The species of fungus that infected the prehistoric ant may be an ancestor of zombie-ant fungi, and thus likely controlled its host's body in similar ways, said study coauthor João Araújo, mycology curator and assistant professor at the Danish Natural History Museum. Very few specimens of ancient parasitic fungi have been discovered, so little is known about their evolution. The two insects were likely killed by the fungi before getting trapped in the sticky tree resin that ultimately forms amber, said Araújo, noting that most entomopathogenic fungi kill their hosts to produce the fruiting body. This lost parasite diversity had a significant role in shaping the planet we live on today, said Phil Barden, an associate professor at New Jersey Institute of Technology's department of biological sciences, who has worked on amber fossils. 'Even as we find a remarkable diversity of organisms entombed in amber, it's important to remember that we really do only capture the smallest glimpse. For any given fossil ant or beetle, we can imagine all of the parasites, fungus, and bacteria that such insects support,' Barden, who wasn't involved in the new study, said via email. It was 'fascinating to see some of the strangeness of the natural world that we see today was also present at the height of the age of the dinosaurs,' said study coauthor Edmund Jarzembowski, a professor and associate scientist at London's Natural History Museum. The fossil is the latest to emerge from Myanmar's rich amber fields. While amber fossils have been some of paleontology's most exciting finds in recent years, ethical concerns about the provenance of amber from the civil war-torn region have emerged. Zhuang said the fossils were sourced from Myanmar's amber markets. The study noted that the specimens were acquired before 2017 and, to the authors' knowledge, were not involved in armed conflict or ethnic strife.
Yahoo
an hour ago
- Yahoo
Hemab Therapeutics Presents Positive Clinical and Preclinical Data Across Bleeding Disorder Pipeline at ISTH 2025 Congress
Sutacimig Phase 2 interim results demonstrate >50% reduction in treated bleeding event and prophylactic treatment potential in Glanzmann thrombasthenia HMB-002 clinical proof-of-mechanism data in Von Willebrand disease support its potential as a first-in-class prophylactic therapy by elevating VWF levels and extending half-life Natural history insights illuminate true patient burden and prophylactic opportunity to inform transformative, preventative solutions for underserved bleeding disorders COPENHAGEN, Denmark and CAMBRIDGE, Mass., June 24, 2025 /PRNewswire/ -- Hemab Therapeutics, a clinical-stage biotechnology company developing novel prophylactic therapeutics for serious, underserved bleeding and thrombotic disorders, today announced clinical and preclinical results at the International Society on Thrombosis and Haemostasis (ISTH) 2025 Congress in Washington, DC. The company's 11 abstracts present breakthrough data for sutacimig (formerly HMB-001) and HMB-002, its lead therapeutic candidates, along with crucial insights from natural history studies. "The data presented at ISTH underscore the potential for Hemab's impact in addressing the severe unmet needs of people with bleeding disorders," said Kate Madigan, Chief Medical Officer at Hemab. "Our sutacimig and HMB-002 data reveal important progress towards transformative, preventative solutions for these devastating diseases. We're demonstrating the possibilities to meaningfully reduce bleeding and elevate care for people living with Glanzmann thrombasthenia and Von Willebrand disease." Highlights of Clinical Presentations Sutacimig shows promising safety and efficacy in Glanzmann thrombasthenia (GT). The Phase 2 study is fully enrolled (N=34 in Part B), and data show a clinically meaningful reduction in treated bleeding events. Clinically meaningful bleeding reduction: Sutacimig treatment in the efficacy population (n=33) demonstrated a >50% reduction in median Annualized Treated Bleeding Rate (ATBR), with the median ATBR decreasing from 21.2 to 4.61. Select patient reports indicate a reduced severity of bleeds and decreased IV rFVIIa use. Safety profile: Sutacimig demonstrated a favorable safety profile, with most adverse events (AEs) being mild to moderate in severity, and no reported thromboses or discontinuations due to AEs in ongoing dose levels of 0.3 and 0.6 mg/kg. PK/PD insights: At ongoing dose levels of 0.3 and 0.6 mg/kg, Factor VIIa (FVIIa) accumulation reached 2-4 fold above baseline. Exploratory thrombin generation assays suggested hemostatic activity, with observed improvements comparable to those seen with clinically relevant concentrations of rFVIIa. Late Breaking Abstract presentation of HMB-002 demonstrates positive proof of mechanism in Von Willebrand disease (VWD), with the first-in-human VELORA Pioneer study in Type 1 VWD patients. Favorable safety profile: No treatment-emergent AEs, injection-site reactions, hypersensitivity, or serious AEs were reported in the VELORA Pioneer Cohort A1. Encouraging endogenous Von Willebrand Factor (VWF) and FVIII accumulation: The VELORA Pioneer study demonstrated that the initial single 20mg subcutaneous dose of HMB-002 induced consistent and sustained increases in VWF and Factor VIII FVIII levels. Within 14 days, mean VWF rose >1.5-fold from baseline. Normalized APTT and improved thrombin generation: Parallel to the increases in VWF, levels of Factor VIII were corrected, resulting in normalization in APTT and thrombin generation. Preclinical data highlights Sutacimig enhances rFVIIa efficacy in in vitro studies, enabling potentially lower doses for breakthrough bleeds. Studies also show sutacimig preserves the function of stored platelet concentrates (PCs), supporting its mechanism that could reduce both rFVIIa doses and PC volumes needed for bleeding control. Nonclinical safety evaluations of HMB-002 in cynomolgus monkeys and in vitro/ex vivo assays showed no adverse effects, immunotoxicity (including complement and platelet activation or cytokine release), or off-target binding, indicating a favorable safety profile. Extended half-life and infrequent dosing: Pharmacokinetic modeling estimated a long HMB-002 half-life, supporting infrequent subcutaneous dosing. In studies with cynomolgus monkeys, HMB-002 also extended exogenously administered recombinant VWF's half-life, leading to the time-dependent accumulation of endogenous VWF and FVIII, and resulted in an approximately 3-fold prolongation of recombinant VWF in circulation. Natural history highlights GT: Recent findings complementing previous natural history data confirm the severe, often underestimated disease burden of GT. The ATHN Transcends GT study quantifies this with a mean Annualized Bleeding Rate (ABR) of 72.0, with most bleeds requiring treatment (ATBR of 51.9) and 56% of participants experiencing a severe disease burden. A separate retrospective analysis of US-based real-world patient records reveals how this frequent blood loss initiates a self-perpetuating cycle of blood loss and iron deficiency anemia that worsens complications for all patients. This cycle creates a disproportionate unmet need for women, who report high rates of hemorrhage (75%) and anemia (23%), often triggered by heavy menstrual bleeding. Men are also heavily burdened, with significantly higher rates of gastrointestinal bleeding (36%) and hematomas (30%). A systematic care gap compounds the clinical crisis: management is mainly limited to on-demand treatments administered post-bleed, and a large proportion of patients are cared for outside of specialized hematology centers, contributing to ongoing underdiagnosis and underestimation of disease prevalence. This highlights a critical need for improved access to expert care and effective prophylactic therapies for all individuals with GT. VWD: New lived-experience data from the VWD360 study reveals a much higher than previously reported unmet need in VWD, highlighting a significant socioeconomic and psychological burden, especially the disproportionate impact on women suffering from heavy menstrual bleeding. The study found that participants averaged 1.33 bleeds weekly, with 71% missing work and high rates of low mood (73%). Crucially, data from a VWD360 substudy and VELORA Discover challenge historical assumptions, showing Type 1 VWD bleeding rates are comparable to, or even higher than, other subtypes, revealing a major care gap for this neglected patient population. Benny Sorensen, MD, PhD, CEO of Hemab, stated, "Our multiple ISTH presentations underscore Hemab's commitment to leveraging the biotechnological revolution and deep hemostasis expertise to develop innovative prophylactic therapies for patients with bleeding disorders. Our dedication to always listening to the people living with these diseases has generated extensive natural history data revealing substantially greater unmet medical need than previously recognized, driving our continued clinical advancement." About Glanzmann ThrombastheniaGlanzmann thrombasthenia (GT) is a severe bleeding disorder marked by debilitating, sometimes life-threatening bleeding episodes. Results from an international Glanzmann's 360 (GT360) natural history study revealed the substantial burden of this disease: 88% of the 117 participants reported at least one bleed in the previous week, with 34% of those bleeds requiring medical treatment. These bleeding episodes significantly impact patients' mental health and quality of life, with 67% reporting low mood, 52% reporting emotional problems, and 46% experiencing social isolation. Additionally, 81% of participants reported missing school or work due to bruising or bleeding. To date, there are no effective prophylactic treatment options for GT. About Sutacimig (formerly HMB-001)Sutacimig is a subcutaneously administered bispecific antibody that binds and stabilizes endogenous Factor VIIa with one antibody arm and binds to TLT-1 on activated platelets with the other arm. This mechanism allows for the accumulation of endogenous Factor VIIa in the body and recruitment of Factor VIIa directly to the surface of the activated platelets, where it facilitates hemostatic plug formation. Sutacimig is designed to be a first-in-class prophylactic treatment for Glanzmann thrombasthenia (GT) with the potential to treat other debilitating bleeding disorders. The U.S. Food and Drug Administration granted Fast Track Designation and Orphan Drug Designation to sutacimig for the treatment of GT while the UK Medicines and Healthcare products Regulatory Agency has awarded it designation under the Innovative Licensing and Access Pathway (ILAP). For more information, please visit (NCT06211634). About Von Willebrand DiseaseVon Willebrand Disease (VWD) is the most common inherited bleeding disorder, characterized by quantitative or qualitative defects in Von Willebrand Factor (VWF), often resulting in frequent mucocutaneous bleeding events and heavy menstrual bleeding in women. The severity of bleeding ranges from low-volume events to potentially life-threatening hemorrhages. Chronic blood loss frequently leads to iron deficiency anemia, exacerbating the disease burden and reducing quality of life, particularly for those with clinically understated subtypes. Despite its prevalence, current treatment options for VWD primarily focus on managing symptoms rather than addressing the underlying defect in VWF production or function. About HMB-002HMB-002 is a monovalent human antibody developed as the first-in-class prophylactic treatment for Von Willebrand Disease targeting the underlying root cause of the disease, a condition driven by a deficiency or defect in Von Willebrand Factor (VWF), a key regulator of hemostasis. By specifically targeting the C-terminal CK domain of VWF, which is distinct from regions critical to its essential interactions, HMB-002 shields the protein from degradation, boosting endogenous levels without compromising its function. Clinical and nonclinical data suggest strong potential for meaningful therapeutic benefit. For more information, please visit (NCT06610201 and NCT06754852). About Hemab TherapeuticsHemab is a multiple clinical-asset biotechnology company developing novel prophylactic therapeutics for serious, underserved bleeding and thrombotic disorders. Based in Cambridge, MA, and Copenhagen, Denmark, Hemab is progressing a pipeline of innovative therapeutic solutions, leveraging a variety of cutting-edge technologies and approaches to transform the treatment paradigm for patients with high unmet need. The company's strategic guidance, Hemab 1-2-5TM, targets building a pipeline of development programs to deliver long-awaited innovation for patients with high unmet need diseases like Glanzmann thrombasthenia, Factor VII Deficiency, Von Willebrand Disease, and others. Learn more at Follow us on LinkedIn, Facebook, Instagram, and X. Media Contact:Peg View original content to download multimedia: SOURCE Hemab Therapeutics
